# Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

> **NCT01520909** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 92 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01520909
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520909, "Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01520909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*